226 related articles for article (PubMed ID: 33307885)
1. Cost-effectiveness of vortioxetine compared with levomilnacipran and vilazodone in patients with major depressive disorder switching from an initial antidepressant.
Atsou K; Ereshefsky L; Brignone M; Danchenko N; Diamand F; Mucha L; Touya M; Becker R; François C
Expert Rev Pharmacoecon Outcomes Res; 2021 Feb; 21(1):29-42. PubMed ID: 33307885
[No Abstract] [Full Text] [Related]
2. Efficacy and safety of levomilnacipran, vilazodone and vortioxetine compared with other second-generation antidepressants for major depressive disorder in adults: A systematic review and network meta-analysis.
Wagner G; Schultes MT; Titscher V; Teufer B; Klerings I; Gartlehner G
J Affect Disord; 2018 Mar; 228():1-12. PubMed ID: 29197738
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of different doses of three new antidepressants for treating major depressive disorder: A PRISMA-compliant meta-analysis.
He H; Wang W; Lyu J; Zheng J; Guo L; An X; Fan Y; Ma X
J Psychiatr Res; 2018 Jan; 96():247-259. PubMed ID: 29127931
[TBL] [Abstract][Full Text] [Related]
4. A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine.
Deardorff WJ; Grossberg GT
Expert Opin Pharmacother; 2014 Dec; 15(17):2525-42. PubMed ID: 25224953
[TBL] [Abstract][Full Text] [Related]
5. Vortioxetine for major depressive disorder: An indirect comparison with duloxetine, escitalopram, levomilnacipran, sertraline, venlafaxine, and vilazodone, using number needed to treat, number needed to harm, and likelihood to be helped or harmed.
Citrome L
J Affect Disord; 2016 May; 196():225-33. PubMed ID: 26938965
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of vortioxetine versus venlafaxine (extended release) in the treatment of major depressive disorder in South Korea.
Choi SE; Brignone M; Cho SJ; Jeon HJ; Jung R; Campbell R; Francois C; Milea D
Expert Rev Pharmacoecon Outcomes Res; 2016 Oct; 16(5):629-638. PubMed ID: 26641142
[TBL] [Abstract][Full Text] [Related]
7. The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone.
McIntyre RS
Neuropsychiatr Dis Treat; 2017; 13():2913-2919. PubMed ID: 29238196
[TBL] [Abstract][Full Text] [Related]
8. P-glycoprotein differentially affects escitalopram, levomilnacipran, vilazodone and vortioxetine transport at the mouse blood-brain barrier in vivo.
Bundgaard C; Eneberg E; Sánchez C
Neuropharmacology; 2016 Apr; 103():104-11. PubMed ID: 26700248
[TBL] [Abstract][Full Text] [Related]
9. Vilazodone, levomilnacipran and vortioxetine for major depressive disorder: the 15-min challenge to sort these agents out.
Citrome L
Int J Clin Pract; 2015 Feb; 69(2):151-5. PubMed ID: 25627335
[No Abstract] [Full Text] [Related]
10. Cost per successfully treated patient for vortioxetine versus duloxetine in adults with major depressive disorder: an analysis of the complete symptoms of depression and functional outcome.
Christensen MC; Munro V
Curr Med Res Opin; 2018 Apr; 34(4):593-600. PubMed ID: 29235884
[TBL] [Abstract][Full Text] [Related]
11. Vortioxetine: a novel antidepressant for the treatment of major depressive disorder.
Gonda X; Sharma SR; Tarazi FI
Expert Opin Drug Discov; 2019 Jan; 14(1):81-89. PubMed ID: 30457395
[TBL] [Abstract][Full Text] [Related]
12. Successfully treated patients with vortioxetine versus venlafaxine: a simplified cost-effectiveness analysis based on a head-to-head study in Asian patients with major depressive disorder.
Wang G; Zhao K; Reynaud-Mougin C; Loft H; Ren H; Eriksen HF; Ettrup A
Curr Med Res Opin; 2020 May; 36(5):875-882. PubMed ID: 31990207
[No Abstract] [Full Text] [Related]
13. Cost-utility analysis of vortioxetine versus agomelatine, bupropion SR, sertraline and venlafaxine XR after treatment switch in major depressive disorder in Finland.
Soini E; Hallinen T; Brignone M; Campbell R; Diamand F; Cure S; Aalto-Setälä M; Danchenko N; Koponen H; Kolasa K
Expert Rev Pharmacoecon Outcomes Res; 2017 Jun; 17(3):293-302. PubMed ID: 27680105
[TBL] [Abstract][Full Text] [Related]
14. Perspectives on the impact of vortioxetine on the treatment armamentarium of major depressive disorder.
Cuomo A; Barillà G; Cattolico M; Pardossi S; Mariantoni E; Koukouna D; Carmellini P; Fagiolini A
Expert Rev Neurother; 2024 May; 24(5):465-476. PubMed ID: 38536761
[TBL] [Abstract][Full Text] [Related]
15. Pharmacotherapy of major depression in late life: what is the role of new agents?
Patel K; Abdool PS; Rajji TK; Mulsant BH
Expert Opin Pharmacother; 2017 Apr; 18(6):599-609. PubMed ID: 28317392
[TBL] [Abstract][Full Text] [Related]
16. Switching to sertraline or venlafaxine after failure of SSRIs treatment in major depressive disorder: an economic evaluation of the STAR*D trial.
Leelahanaj T
J Med Assoc Thai; 2012 May; 95 Suppl 5():S29-37. PubMed ID: 22934442
[TBL] [Abstract][Full Text] [Related]
17. Health resource use and costs of vilazodone and other selective serotonin re-uptake inhibitors in treating major depressive disorder.
Zhou ZY; Sun S; Chopra P; Zhong Y; Totev T; Signorovitch J
J Med Econ; 2015; 18(11):919-29. PubMed ID: 26121061
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of vilazodone for the treatment of depressive and anxiety disorders.
Stuivenga M; Giltay EJ; Cools O; Roosens L; Neels H; Sabbe B
Expert Opin Pharmacother; 2019 Feb; 20(3):251-260. PubMed ID: 30475091
[TBL] [Abstract][Full Text] [Related]
19. The Preclinical and Clinical Effects of Vilazodone for the Treatment of Major Depressive Disorder.
Sahli ZT; Banerjee P; Tarazi FI
Expert Opin Drug Discov; 2016; 11(5):515-23. PubMed ID: 26971593
[TBL] [Abstract][Full Text] [Related]
20. Comparative evaluation of vortioxetine as a switch therapy in patients with major depressive disorder.
Thase ME; Danchenko N; Brignone M; Florea I; Diamand F; Jacobsen PL; Vieta E
Eur Neuropsychopharmacol; 2017 Aug; 27(8):773-781. PubMed ID: 28663124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
